These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38100174)

  • 1. Terlipressin plus albumin in patients with HRS listed for liver transplant: Treat early and avoid RRT.
    Juanola A; Cárdenas A
    Liver Transpl; 2024 Apr; 30(4):335-336. PubMed ID: 38100174
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
    Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
    Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
    Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [TBL] [Abstract][Full Text] [Related]  

  • 5.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
    Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
    Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
    Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
    Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
    Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
    United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
    Boyer TD; Sanyal AJ; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Gülberg V; Sigal S; Bexon AS; Teuber P;
    Liver Transpl; 2011 Nov; 17(11):1328-32. PubMed ID: 21837734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
    Allegretti AS; Subramanian RM; Francoz C; Olson JC; Cárdenas A
    Liver Int; 2022 Oct; 42(10):2124-2130. PubMed ID: 35838488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
    Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
    Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
    N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
    Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
    Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatorenal syndrome in patients with cirrhosis.
    Moreau R
    J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
    Salerno F; Gerbes A; Ginès P; Wong F; Arroyo V
    Gut; 2007 Sep; 56(9):1310-8. PubMed ID: 17389705
    [No Abstract]   [Full Text] [Related]  

  • 20. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
    Gifford FJ; Morling JR; Fallowfield JA
    Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.